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We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D).  
Research Design and Methods  
732 recently diagnosed T2D patients from the IMI-DIRECT study were extensively phenotyped 
over three years, including measures of insulin sensitivity (OGIS), β-cell glucose sensitivity (GS) 
and insulin clearance (CLIm) from mixed meal tests, liver enzymes, lipid profiles, and baseline 
regional fat from MRI. The associations between the longitudinal metabolic patterns and HbA1c 
deterioration, adjusted for changes in BMI and in diabetes medications, were assessed via stepwise 
multivariable linear and logistic regression.  
Results 
Faster HbA1c progression was independently associated with faster deterioration of OGIS and GS, 
and increasing CLIm; visceral or liver fat, HDL-cholesterol and triglycerides had further 
independent, though weaker, roles (R2=0.38). A subgroup of patients with a markedly higher 
progression rate (fast progressors) was clearly distinguishable considering these variables only 
(discrimination capacity from AUROC=0.94). The proportion of fast progressors was reduced from 
56% to 8-10% in subgroups in which only one trait among OGIS, GS and CLIm was relatively 
stable (odds ratios 0.07 to 0.09). T2D polygenic risk score and baseline pancreatic fat, GLP-1, 
glucagon, diet, and physical activity did not show an independent role.  
Conclusions 
Deteriorating insulin sensitivity and β-cell function, increasing insulin clearance, high visceral or 
liver fat, and worsening of the lipid profile are the crucial factors mediating glycemic deterioration 
 
 
of T2D patients in the initial phase of the disease. Stabilization of a single trait among insulin 
sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression.   
 
 
Maintaining glucose levels within appropriate limits in patients with type 2 diabetes (T2D) is a 
crucial factor to prevent complications. Effective strategies to slow glycemic progression can be 
supported by understanding the processes underlying deterioration of glucose control.  
Few studies have assessed HbA1c trajectories and the possible determinants of glycemic 
deterioration. An established finding is that β-cell function decline is an important factor (1,2), 
while contradictory conclusions were drawn for insulin sensitivity (1,3–7). Whether heterogeneous 
patterns between patients exist in β-cell function and insulin sensitivity decline has not been 
clarified, an important question for patient stratification and personalized medicine. Other 
limitations of previous analyses include the incomplete characterization of the metabolic parameters 
affecting glucose homeostasis (derived using fasting data only (2,4)), the restricted set of traits 
investigated together, and the lack of potentially relevant measures such as ectopic fat, insulin 
clearance, or lifestyle. No study has assessed the relationships between the longitudinal trajectories 
of HbA1c and those of the other metabolic traits.  
In this analysis, we have used data from the cohort of recently diagnosed and extensively 
phenotyped T2D patients of the DIRECT study (8,9) to elucidate the processes underlying glycemic 
deterioration. Specific features of the DIRECT study are the detailed assessment of the glucose 
homeostasis parameters, and patients all being in the initial phase of the disease. We determined the 
patterns over a 3-year period of HbA1c, β-cell function, insulin sensitivity and other relevant 
laboratory, clinical and functional parameters, and assessed their relevance in the deterioration of 
glucose control.  
Research Design and Methods  
Subjects and protocol  
The IMI-DIRECT (Innovative Medicines Initiative - Diabetes Research on Patient Stratification) 
project is a multicenter prospective study on northern European adults (8,9) (ClinicalTrials.gov 
 
 
identifier NCT03814915). The present analysis considers the DIRECT cohort of recently diagnosed 
T2D patients, who were recruited according to the following criteria: white race, T2D diagnosis 
according to the American Diabetes Association 2011 criteria (10) not less than 6 months and not 
more than 24 months before baseline examination, previous treatment via lifestyle measures with or 
without metformin therapy, age between 35 and 74 years, BMI between 20 and 50 kg/m2, estimated 
glomerular filtration rate >50 ml/min, and HbA1c concentration <7.64 % (60.0 mmol/mol) within 
the previous 3 months. Participants were studied at baseline (month 0) and at months 9, 18 and 36. 
Subjects with HbA1c available at least in two visits were included in this analysis (N=750).  
All participants provided written informed consent and the study protocol was approved by the 
regional research ethics review boards. The research conformed to the ethical principles for medical 
research involving human participants outlined in the declaration of Helsinki.  
Collected data  
Anthropometric data, HbA1c, blood lipids and liver enzymes were collected at all visits. A 27-month 
HbA1c sample was collected in 39 patients. A standardized mixed meal test (8) (MMTT) was 
performed at months 0, 18 and 36 to calculate indices of insulin sensitivity (in fasting conditions, 
QUICKI (11), and post-MMTT, OGIS (12)), β-cell function (13) (glucose sensitivity, GS, and rate 
sensitivity), and insulin clearance (in fasting conditions, and post-MMTT, CLIm). From the 
baseline visit we collected glucagon, proinsulin and glucagon-like peptide 1 (GLP-1), measures of 
regional fat from MRI (8) (available in 561 participants), of physical activity from accelerometer 
(8), and of self-reported 24-hour nutrient intake (8), and we computed the fatty liver index (FLI) 
(14) and a T2D polygenic risk score (PRS) (15). The whole set of traits considered in this study is 
described in detail in the Supplemental Material (DATA, METHODS, and Table S2).  
Assessment of progression rates  
 
 
We computed the progression rates for HbA1c and several traits available at follow up 
(Supplemental Table S4). Each trajectory was described with a conditional linear mixed-effect 
model (16), in which the longitudinal component of the data was described as a proportional 
function of time, with normally distributed slopes describing individual progression rates. HbA1c 
progression was adjusted for changes in BMI and diabetes medications, which were recorded at all 
visits (as dosage and start and end of treatment). The adjustments were assumed to be 1) 
proportional to BMI; 2) linearly related to the metformin dose, expressed as percentage of a 
maximal dose of 3 grams; 3) linearly related to the cumulative dose for the other antidiabetic drugs 
(insulin excluded), expressed as sum of the percentages of the maximum dose of each drug; 4) 
constant under insulin treatment. A proportional effect of delay in HbA1c assay, i.e. of the difference 
between the time of measurement and the time of sample collection, was also introduced. 
Medications were considered to be effective if taken at least 30 days before HbA1c measurement. 
OGIS and QUICKI trajectories were adjusted for changes in BMI. Further details about the 
conditional linear mixed-effect models are provided in the Supplemental Material (METHODS).  
Statistical analysis  
Results are presented for participants (N=732) with GAD <11 U/ml and islet antigen-2 antibodies 
(IA-2) <7.5 U/ml, to exclude other possible forms of diabetes (17). Distributions are described as 
mean ± standard deviation. Pairwise associations between continuous variables were assessed using 
the Spearman correlation coefficient; differences between groups were assessed using the Wilcoxon 
signed rank test (for two groups) and Kruskal-Wallis test (for three or more groups).  
We used stepwise multivariable linear regression to determine the set of variables, as baseline 
values (Table S2) and progression rates (Table S4), independently associated with the HbA1c 
progression rate, with adjustment for center, sex and age. For baseline variables, both 
untransformed and transformed values were considered; transformations were logarithmic, or logit 
when variables where constrained within an interval. The independent variables were included in 
 
 
the regression model when their effects had p<0.05 and produced an increment in the adjusted R2 
value. Two stepwise analyses were performed: one on all participants, excluding MRI variables 
from the analysis, and one on the subset of participants with MRI data, including this data in the 
analysis. Standardized coefficients were computed per standard deviation of the underlying data 
distribution. 
Since the distribution of HbA1c progression rates was skewed to the right with a group of patients 
with high values, we split the subjects into average and fast progressors according to a progression 
rate threshold (see Results). We used multivariable logistic regression to assess the odds ratios of 
average vs fast progression, using the independent variables identified in the multiple linear 
regression analysis of HbA1c progression. The logistic analysis provided values for area under the 
receiver operating characteristic, sensitivity, specificity, and accuracy to be used as measures of the 
discrimination capacity of the investigated independent variables over fast versus average 
progressors. These parameters must not be interpreted as measures of predictive capacity. 
The logistic analysis provided values for AUROC, sensitivity, specificity and accuracy, to be used 
as measures of the discrimination capacity of the investigated independent variables over fast vs 
average progressors. These parameters must not be interpreted as measures of predictive capacity. 
Role of the funding source  
The funders had no role in study design, in collection, analysis, and interpretation of data, in writing 
of the report, or in the decision to submit the paper for publication. The corresponding author had 
full access to all data and had final responsibility for the decision to submit for publication.  
Results  
Subjects’ baseline characteristics  
 
 
At baseline, the participants had age of 62±8 years, were moderately obese (30.4±4.9 kg/m2 BMI), 
and had HbA1c of 6.41±0.53 % (46.5±5.8 mmol/mol) and fasting glucose of 7.1±1.4 mmol/l. (Table 
S2). 34% of the subjects were treated with metformin at baseline, the rest was treatment naïve.  
Progression rates of HbA1c and other traits  
The individual HbA1c progression rates (Supplemental Figure S1), adjusted for changes in BMI and 
in diabetes medications, were on average only slightly positive and mostly distributed close to their 
median (median, first and ninth deciles were 0.041, -0.038 and 0.185 %/year (0.45, -0.41 and 2.02 
mmol mol-1 year-1), respectively). However, the distribution showed a heavy right tail with values 
up to 0.897 %/year (9.8 mmol mol-1 year-1). The adjustment of progression rates for BMI changes 
implied a standardized coefficient for the BMI effect of 0.37.  
All the other investigated traits had a mean progression rate per year smaller, in absolute value, than 
5% of the corresponding baseline average (see Table S5 for details). On average, waist 
circumference, but not BMI, increased very slightly. Insulin sensitivity (as OGIS) and most of the 
β-cell function parameters decreased. Fasting, but not post-meal, insulin clearance decreased. Total 
cholesterol did not change, while its fractions showed opposite changes, with HDL increasing and 
LDL decreasing; TG increased. Creatinine and ALT did not change, while AST and AST/ALT 
increased.  
Several pairwise associations were observed between HbA1c progression rate and laboratory, 
clinical, and functional parameters (Supplemental Figure S2). In particular, HbA1c progression rate 
was clearly associated (p<0.01) with some baseline traits (positively with BMI, waist 
circumference, triglycerides, glucagon, liver and visceral fat; inversely with age, HDL, insulin 
sensitivity, and β-cell function) and some progression rates (positively with those of triglycerides 




Several pairwise associations were also observed between the progression rates of the investigated 
traits (Figure S2, panel B). GS and OGIS progression rates were independent of one another despite 
HbA1c progression rate being associated with both of them.  
Variables associated with HbA1c progression rate: multivariable linear analysis  
In multivariable linear analysis of HbA1c progression rate in all patients, the baseline values and the 
progression rates of several traits provided an independent contribution (adjusted R2 0.38; Figure 1, 
panel A). Faster HbA1c progression was independently associated with lower baseline values and 
faster deterioration of insulin sensitivity (as OGIS) and β-cell function (mostly as glucose 
sensitivity, GS), with higher baseline values of MMTT insulin clearance, CLIm, and with its 
increase (all p-values <0.001). Faster HbA1c progression was also independently associated with 
lower baseline HDL (p<0.05) or its slower increase (p<0.001), with a quicker increase of TG 
(p<0.001), as well as with higher baseline values of BMI (p<0.01) and lower baseline values of 
HbA1c (p<0.001). The variables with strongest effects were the baseline OGIS value and the 
progression rates of OGIS, GS and CLIm (standardized coefficients, in absolute value, between 
0.24 and 0.57).  
In multivariable analysis of the subset of patients with baseline MRI measurements (adjusted R2 
0.40; Figure 1, panel B), baseline visceral fat was positively and independently correlated with 
HbA1c progression rate; moreover, female sex and younger age independently predicted faster 
HbA1c progression. The role of the other key metabolic parameters, OGIS, GS and CLIm, remained 
similar. Replacing visceral fat with liver fat produced similar results (standardized coefficient equal 
to 0.15 for visceral fat, to 0.11 for liver fat); when both visceral and liver fat were included in the 
model, the latter was not independently associated with HbA1c progression.  
No independent effects were detected for smoking status, family history, T2D polygenic risk score, 
baseline values of diet, physical activity, pancreatic fat, GLP-1 (total and intact at fasting, total at 60 
min), glucagon, and 60-min proinsulin, baseline values and progression rates of AST and ALT.  
 
 
Further details on the multivariable linear analysis are reported in the Supplemental Material 
(RESULTS).  
Variables associated with HbA1c progression rate: multivariable logistic analysis  
The threshold selected to separate the heavy right tail of the distribution of HbA1c progression rates 
was 0.255 %/year (2.79 mmol mol-1 year-1). This threshold split the subjects into average 
progressors (N=699), with a progression rate of 0.044±0.076 %/year (0.48±0.83 mmol mol-1 year-1), 
and fast progressors (N=33), with a ~10-fold mean progression rate (0.460±0.185 %/year, 
5.03±2.02 mmol mol-1 year-1) (Figure 2).  
We found that the trajectories of most variables independently affecting HbA1c progression as from 
the linear analysis were clearly different (p<0.001) in the two groups (Figure 2): in fast progressors, 
OGIS and GS strongly declined and TG and CLIm markedly increased. At baseline, fast 
progressors had lower OGIS (p<0.05), CLIm (p<0.01) and HDL (p<0.001), and higher BMI 
(p<0.01).  
Logistic analysis substantially confirmed the results of linear regression (Figure 1), with half the 
investigated variables still contributing (p<0.05) to distinguish average and fast progressors (Figure 
3): fast HbA1c progression independently associated with stronger deterioration and a lower 
baseline value of OGIS and GS, CLIm increase, and HDL reduction. The discrimination capacity of 
the logistic model, computed as AUROC, was 0.94 (95% CI between 0.86 and 0.98).  
Similar outcomes were obtained using lower HbA1c progression rate thresholds, which resulted in 
larger numbers of patients classified as fast progressors (Supplemental Material - RESULTS, 
Figures S1 and S3).  
At baseline, the percentage of patients treated with metformin were not different between fast 
progressors (39.4% [24.7-56.3%, 95% CI]) and average progressors (33.9% [30.5-37.5%], p = 
0.64). At the last visit, the percentage of patients treated with any diabetes medication was 
 
 
somewhat higher in fast progressors, as expected (p = 0.048, details provided in the Supplemental 
Material - RESULTS). Only 7 average progressors were on insulin at the last visit. 
Impact of stable OGIS, GS or CLIm on proportion of fast HbA1c progressors  
Because HbA1c progression was associated with worsening of three main factors, OGIS, GS and 
CLIm, we have evaluated the possible importance of maintaining one of these key traits relatively 
stable in order to avoid fast progression. For this purpose, we considered each trait as deteriorating 
if its progression rate fell within its worst tertile (the bottom tertile for OGIS and GS, the top one 
for CLIm), and as stable if it fell in the other two tertiles. We examined the subgroups of patients in 
which none or only one of these key traits was relatively stable (Table 1).  
We found that the proportion of fast progressors was 56% in the patient subgroup where GS, OGIS 
and CLIm were all deteriorating, and decreased to 8-10% in the subgroups where a single trait, 
either GS, OGIS or CLIm, was stable. All proportions were different from 0 at 90% confidence 
level, stressing that fast progression did not imply quick changes for each of the three considered 
traits. All differences in proportions (one stable trait vs none) had p<0.001, and were associated to 
odds ratio for fast vs average progression below 0.1 (Table 1); thus, relatively stable progression 
rate of one single trait among GS, OGIS and CLIm was strongly associated to reduced glycemic 
deterioration.  
Conclusions  
Leveraging on the detailed participant characterization of the DIRECT study, we have been able to 
elucidate the processes underlying glycemic deterioration in T2D patients in the initial phase of the 
disease. We found that HbA1c deterioration was independently associated with 1) a decrease in 
insulin sensitivity; 2) a decrease in β-cell function (primarily β-cell glucose sensitivity); 3) an 
increase in insulin clearance; 4) lower values of insulin sensitivity and glucose sensitivity and 
 
 
higher values of insulin clearance at baseline. Further variables independently associated with faster 
HbA1c progression were declining HDL, increasing TG and high baseline visceral or liver fat.  
The variables identified by multivariable linear analysis also explained the rapid HbA1c 
deterioration detected in a subset of patients (identified as fast progressors), the strongest predicting 
variables of the multivariable linear model being significant also with logistic analysis. Clear 
differences were evident between fast and average HbA1c progressors (Figure 2), consistent with the 
associations derived from the multivariable linear analysis. The high discrimination capacity of the 
logistic analysis suggests that the selected variables capture the most relevant pathophysiological 
factors underlying glycemic deterioration.  
The independent associations with HbA1c progression of several variables, in particular the 
progression rates of insulin sensitivity, β-cell function and insulin clearance, and the existence of 
fast HbA1c progressors with relatively stable conditions for any of these three traits (Table 1), 
indicates 1) that the processes of glycemic deterioration are heterogeneous in this population of 
T2D patients; 2) that fast progression does not imply quick deterioration of a specific trait, e.g. 
insulin sensitivity or β-cell function.  
The dichotomous analysis shows that the odds for fast vs average progression are substantially 
reduced when either glucose sensitivity, insulin sensitivity or insulin clearance is relatively stable. 
Although these findings do not demonstrate causality, they suggest that preventing either high 
degradation rates of glucose sensitivity or insulin sensitivity, or high increase rates of insulin 
clearance, may be an effective strategy to slow down glycemic deterioration in the initial phase of 
the disease. This reemphasizes the importance of lifestyle interventions aiming at controlling insulin 
resistance, as preventing deterioration of the other traits currently appears more difficult.  
This study also shows that insulin resistance plays a major role in glycemic deterioration in these 
T2D patients. In particular, we show associations of glycemic deterioration with baseline insulin 
sensitivity and its longitudinal change that the Belfast Diet Study (1), UKPDS (4,18) and ADOPT 
 
 
(6) could not identify, possibly due to differences in subject selection or to the use of post-MMTT 
vs fasting insulin sensitivity indices. We also demonstrate that the associations between glycemic 
deterioration and insulin sensitivity are independent from both the baseline value and the 
progression rate of the β-cell function, and that insulin resistance progresses independently from β-
cell glucose sensitivity. Since in our analysis both HbA1c and insulin sensitivity trajectories were 
adjusted for BMI changes and BMI did not increase on average, we can conclude that worsening of 
insulin resistance in T2D and the associated glycemic deterioration are partly independent from 
BMI changes. Whether the observed average increases in TG and AST (whose progression rates 
were inversely correlated with OGIS progression rate) have a role in insulin sensitivity deterioration 
(19), and whether this is mediated by ectopic fat accumulation (20), deserves further study.  
UKPDS 25 and 26 (4,18), the Belfast Diet Study (1) and the ADOPT study (6) identified baseline 
HOMA-%B as a predictor of glycemic deterioration (insulin requirement within 6 years for 
UKPDS, time of failure to dietary therapy for the Belfast Diet Study, and monotherapy failure 
before 4 years for ADOPT). Our study confirms the role of β-cell dysfunction as driver of glycemic 
deterioration using a dynamic β-cell function assessment based on a glucose challenge, rather than 
on fasting data only. We show that both baseline β-cell dysfunction (especially β-cell glucose 
sensitivity) and its deterioration over time are independently associated with HbA1c worsening. 
Moreover, we demonstrate that patients with limited or absent deterioration in β-cell function have 
considerably lower odds of rapid glycemic deterioration.  
Another novel finding is the strong and independent association between HbA1c progression and 
insulin clearance during the MMTT, CLIm. To our knowledge, this is the first study examining 
insulin clearance trajectories after T2D onset. We found that higher baseline CLIm and faster CLIm 
increase over time independently associate with faster HbA1c progression. This is consistent with 
the glucose homeostasis mechanisms, as higher CLIm reduces the average insulin levels. Notably, 
we found a positive correlation between insulin sensitivity and insulin clearance, considering both 
 
 
the baseline values of the two traits, in agreement with previous findings (21), and their progression 
rates (Figure S2). However, on average, in spite of a decrease in insulin sensitivity, insulin 
clearance did not decrease. These findings show that, while in pre-diabetic subjects insulin 
clearance reduction may be a way to mitigate the effects of insulin resistance (22), in T2D patients 
this compensation appears present but impaired and contributing to glycemic deterioration. The 
reasons underlying these results remain elusive. The lack of decrease in insulin clearance may be 
explained by the decrease of total MMTT insulin secretion and consequent desaturation of insulin 
utilization (23) only in fast progressors, as in average progressors total insulin secretion slightly 
increased (Figure 2). Whether hepatic or extrahepatic mechanisms underlie these findings cannot be 
determined from this study and deserves further investigation.  
Our results on TG and HDL effects were partially anticipated by a study of the Genetics of Diabetes 
Audit and Research (GoDARTS) (24), where the outcome was the risk of progression to insulin 
treatment. The study identified baseline TG and HDL (besides BMI, sex, and age, year and HbA1c 
at diagnosis) as independent determinants. A later study on the same data (25), investigating the 
baseline determinants of HbA1c progression rate over about 9 years, confirmed an independent 
effect of HDL (together with age, BMI and year at diagnosis) but not of TG. The FIELD study in 
T2D patients on lifestyle measures only revealed that the HDL effect on initiation of oral 
hypoglycemic agents survives the adjustment for HOMA-IR (26). Compared to previous studies 
(24–26) our analysis includes the progression rates of plasma lipid components and baseline MRI 
assessment of regional fat. We show that baseline HDL and BMI, and the progression rates of TG 
and HDL are associated with HbA1c progression, even after accounting for the effects of the three 
main determinants of glucose homeostasis, i.e. insulin sensitivity, β-cell function and insulin 
clearance. In the subset of participants with MRI data, baseline visceral fat or liver fat was 
independently correlated with HbA1c progression rate, a further novel observation. These findings 
suggest that additional lipid-dependent factors contribute to HbA1c deterioration, possible 
 
 
candidates being fat accumulation in the viscera (with excessive supply of fatty acids to the liver 
(27)), liver fat and consequent hepatic insulin resistance (28), or glucose overproduction (29). The 
role of visceral/liver fat supports interventions to reduce ectopic fat as a possible way for slowing 
future glycemic progression.  
Previous studies have reported an inverse correlation between baseline age and HbA1c progression 
(1,4,6,24,25,30). In our analysis, baseline age does not have a clear independent role in the 
multivariable model, most likely because the age range is relatively narrow relative to other studies, 
or because the stronger predictors of HbA1c progression are correlated with age. The latter 
explanation would suggest that the age univariate effect on glycemic deterioration is indirect. We 
do not find a clear sex effect in glycemic deterioration, in agreement with most previous studies 
(1,4,6,24,25). 
In the multivariable model, baseline HbA1c was independently and inversely correlated with HbA1c 
progression rate, in contrast with previous findings (1,4,6,24,30). However, baseline HbA1c was not 
significant in the logistic model. The most likely explanation of this finding is regression to the 
mean: indeed, a random decrease in baseline HbA1c can produce a higher estimate of HbA1c 
progression rate, particularly when the follow-up period is not long, as in our study. Tight glycemic 
control, an inclusion criterion, may have enhanced this effect.  
This study does not find a relevant role of other variables often associated with glucose control. In 
particular, we did not find an effect of smoking status (reported in GPRD (30)), T2D polygenic risk 
score (in agreement with GoDARTS (24)), baseline values of diet, physical activity, pancreatic fat, 
GLP-1, and glucagon. Several of these variables were not associated with HbA1c progression rate 
even in simple correlation analysis (Figure S2). The lack of association for pancreatic fat is 
particularly relevant, and contributes to the ongoing discussion on the role of pancreas fat in T2D 
management (31).  
 
 
In spite of the unique extensive phenotyping of our study and the consistent results, a significant 
limitation is the relatively short follow-up period (3 years). The accuracy of the estimated HbA1c 
progression rate over this time frame may be limited, and in a longer time period the factors 
contributing to progression may differ. In this study, we could not assess the changes over time of 
relevant variables such as regional fat by MRI, diet and physical activity. MRI measurements were 
available only for a subset of subjects. Insulin sensitivity was not derived from the gold standard 
euglycemic clamp. As the cohort included only patients of white race, our findings are not 
generalizable to other racial/ethnic groups. Causal relationships could not be inferred from our 
regression analyses. The study of the mechanisms underlying the deterioration of the factors 
affecting HbA1c progression, an important aspect to envisage optimal treatment strategies, also 
requires further investigation. 
In summary, based on the extensively phenotyped cohort of white European diabetic patients of the 
DIRECT study, we identified decreasing insulin sensitivity, deteriorating β-cell function, increasing 
insulin clearance, high liver or visceral fat, and worsening of the lipid profile as the most important 
factors independently associated with HbA1c deterioration in the early phase of the disease. We also 
showed that patients with a relatively stable value over time of at least one of insulin sensitivity, β-
cell glucose sensitivity, or insulin clearance have considerably reduced odds of fast HbA1c increase. 
This study contributes to the understanding of the factors underlying diabetes progression, 
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Table 1. Proportion of fast HbA1c progressors with different combinations of stable/deteriorating conditions for GS, OGIS and CLIm progression 
rates.  
 Condition*       
































* The progression rate thresholds dividing stable and deteriorating traits for OGIS, GS and CLIm are -16.68 ml min-1 m-2 year-1, -4.07 pmol min-1 m-2 mmol-1 l 
year-1 and 0.0184 l min-1 m-2 year-1, respectively.  
† Two-sided Chi-square test (α=0.05), with Yates continuity correction, on the proportion of fast progressors in the row compared to the same proportion in the 
last row.  
GS: β-cell glucose sensitivity; OGIS: oral insulin sensitivity; CLIm: mixed meal test insulin clearance. 
 
 
Figure legends  
Figure 1. Variables independently associated with HbA1c progression rate from multivariable linear 
analysis. Panel A: all subjects are included in the analysis (625 with all variables), and MRI 
measurements are not considered; panel B: only subjects with MRI are included in the analysis (374 
with all variables), and MRI measurements are taken into consideration. For each variable, the 
figure shows the standardized coefficients ± 95% CI of the effect. Age and HDL were log-
transformed. OGIS: oral insulin sensitivity; CLIm: mixed meal test insulin clearance; GS: β-cell 
glucose sensitivity; TG: fasting triacylglycerol; HDL: fasting HDL-cholesterol; RS: β-cell rate 
sensitivity; progr: progression rate; bas: baseline value; *: p<0.05; **: p<0.01; ***: p<0.001.  
Figure 2. Temporal trajectories or baseline values (bar graphs) of HbA1c and other key traits in fast 
(red lines) and average (blue lines) progressors. Data are mean ± standard error. Simple 
comparisons between fast and average progressors (Wilcoxon rank sum test) are shown for baseline 
values (asterisks at month 0) and progression rates (asterisks at month 18). These comparisons may 
differ from the results of the multivariable analyses (Figures 2 and 4). Sex is not included in the 
figure: males were 42% and 36% in average and fast progressors, respectively (non-significant, 
Chi-squared test). HbA1c values at 27 months are not displayed as they were collected in a subgroup 
of individuals. In average progressors, HbA1c increases from 46.4±0.2 mmol/mol to 46.7±0.3 
mmol/mol; in fast progressors, from 48.9±1.21 mmol/mol to 75.7±2.5 mmol/mol. OGIS: insulin 
sensitivity; CLIm: mixed meal test insulin clearance; GS: β-cell glucose sensitivity; RS: β-cell rate 
sensitivity; TG: fasting triacylglycerol; HDL: fasting HDL-cholesterol; ISRtot: total mixed meal 
test insulin secretion; bas: baseline value; *: p<0.05; **: p<0.01; ***: p<0.001.  
Figure 3. Odds ratios ± 95% CI from the multivariable logistic analysis of fast vs average HbA1c 
progressors. The independent variables are those identified by multivariable linear analysis of 
HbA1c progression, excluding MRI variables (N=625, with 32 fast progressors and 593 average 
progressors). Age and HDL were log-transformed. Values for sensitivity, specificity and accuracy 
 
 
were derived via maximization of balanced accuracy. OGIS: insulin sensitivity; CLIm: mixed meal 
test insulin clearance; GS: β-cell glucose sensitivity; TG: fasting triacylglycerol; HDL: fasting 
HDL-cholesterol; RS: β-cell rate sensitivity; progr: progression rate; bas: baseline value; AUROC: 
area under the receiver operating characteristics; *: p<0.05; **: p<0.01; ***: p<0.001.  
